102 related articles for article (PubMed ID: 19075657)
1. Small molecules ATP-competitive inhibitors of FLT3: a chemical overview.
Schenone S; Brullo C; Botta M
Curr Med Chem; 2008; 15(29):3113-32. PubMed ID: 19075657
[TBL] [Abstract][Full Text] [Related]
2. Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs.
Lan QY; Zhi YL; Heng H; Tian JY; Guo XX; Liu HC; Chen YD; Lu T; Lu S
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):296-322. PubMed ID: 28748750
[TBL] [Abstract][Full Text] [Related]
3. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Garcia JS; Stone RM
Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
[TBL] [Abstract][Full Text] [Related]
4. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
5. FLT3 Inhibitors in the Management of Acute Myeloid Leukemia.
Zappone E; Defina M; Aprile L; Bartalucci G; Gozzetti A; Bocchia M
Anticancer Agents Med Chem; 2017; 17(8):1028-1032. PubMed ID: 27748173
[TBL] [Abstract][Full Text] [Related]
6. The clinical development of FLT3 inhibitors in acute myeloid leukemia.
Knapper S
Expert Opin Investig Drugs; 2011 Oct; 20(10):1377-95. PubMed ID: 21895538
[TBL] [Abstract][Full Text] [Related]
7. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
8. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
9. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
[TBL] [Abstract][Full Text] [Related]
10. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
11. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
Naganna N; Opoku-Temeng C; Choi EY; Larocque E; Chang ET; Carter-Cooper BA; Wang M; Torregrosa-Allen SE; Elzey BD; Lapidus RG; Sintim HO
EBioMedicine; 2019 Feb; 40():231-239. PubMed ID: 30686755
[TBL] [Abstract][Full Text] [Related]
12. Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
[TBL] [Abstract][Full Text] [Related]
13. Novel FLT3 tyrosine kinase inhibitors.
Levis M; Small D
Expert Opin Investig Drugs; 2003 Dec; 12(12):1951-62. PubMed ID: 14640939
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
[TBL] [Abstract][Full Text] [Related]
16. The role of FLT3 kinase as an AML therapy target.
Beffinger M; Skwarska A
Curr Pharm Des; 2012; 18(19):2758-65. PubMed ID: 22390761
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.
Ghiaur G; Levis M
Hematol Oncol Clin North Am; 2017 Aug; 31(4):681-692. PubMed ID: 28673395
[TBL] [Abstract][Full Text] [Related]
18. ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
Ju HQ; Zhan G; Huang A; Sun Y; Wen S; Yang J; Lu WH; Xu RH; Li J; Li Y; Garcia-Manero G; Huang P; Hu Y
Leukemia; 2017 Oct; 31(10):2143-2150. PubMed ID: 28194038
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.
Chen F; Ishikawa Y; Akashi A; Naoe T; Kiyoi H
Oncotarget; 2016 Jul; 7(30):47018-47032. PubMed ID: 27331411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]